company-header-background

GenVoy-ILM™

T Cell Kit for mRNA 

on NanoAssemblr® Ignite™ 

Scale Up Your Cell Therapy with Lipid Nanoparticles 


T-Cell Kit, Spark, Cartridge, Well Plate

Optimized on the NanoAssemblr Spark or Ignite 

Scale Up T Cell Gene Delivery
Lipid nanoparticle (LNP) based technology enables researchers to establish a clinically relevant, scalable method for ex vivo gene delivery.

 

GenVoy-ILM™ T Cell Kit for mRNA, Ignite is an off-the-shelf lipid nanoparticle (LNP) reagent mix optimized for the delivery of messenger RNA (mRNA) or Cas9 mRNA/sgRNA into activated human primary T cells. LNPs are prepared on the NanoAssemblr® Ignite™ instrument with Ignite NxGen™ cartridges. This non-viral delivery method can be seamlessly integrated into any standard human T cell culture workflows using an established protocol with either freshly isolated or cryopreserved T cells.  

GenVoy-ILM T Cell Kit for mRNA, Ignite enables researchers to establish a clinically relevant and scalable method at the preclinical scale for ex vivo gene delivery and editing to accelerate the development of T cell therapies. This kit is also available as GenVoy-ILM™ T Cell Kit for mRNA, Spark for LNPs prepared on NanoAssemblr Spark™.  

 

 

See the Data

Why Use the GenVoy-ILM T Cell Kit for mRNA, Ignite?

 

 

Engineered Cells

Highly Efficient Knockout and Expression

 

Deliver mRNA or mRNA/sgRNA into activated primary T cells consistently with high efficiency

 

See the Data

Engineered Cells

High Cell Viability

 

 

Maintain high T cell viability, even after multi-step cell engineering 

 

See the Data

Scalable from Discovery to Preclinical Icon

Scalable from Discovery to Preclinical


Scale your cell therapy research on the NanoAssemblr platform

 

See the Data

Validated T Cell Manufacturing Workflow

Validated with T Cell Manufacturing Workflow


Optimized and validated for downstream T cell culture workflow   

 

See the Workflow

Move to Clinical Icon

Move to the Clinic with Minimal Hurdles


Accelerate your cell therapy research with this off-the-shelf LNP reagent with a path to the clinic 

Get Started
To learn more about how GenVoy-ILM T Cell Kit for mRNA, Ignite can accelerate your T cell therapy from discovery to clinical applications, contact our Scientific Specialists
Contact a Specialist
Dose-Dependent Transfection Efficiency of GFP with High Cell Viabilities  

Achieve high transfection efficiency with a uniform cell population while maintaining high cell viabilities when delivering GFP mRNA-LNPs into activated human primary T cells. 

 

Viability Graph
Protein Expression Graph 2
Protein Expression
Dose-dependent CD19 CAR expression and cell viabilities in primary T cells. A) Percent CD19 CAR expression and B) Corresponding flow histograms as detected by flow cytometry at the indicated 0.05–4.8 µg RNA/million cell dose. C) Corresponding percent cell viability normalized to untreated controls.  

Dose-Dependent Transfection Efficiency of CD19 CAR with High Cell Viabilities

Achieve high transfection efficiency with a uniform cell population while maintaining high cell viabilities when delivering CD19 CAR mRNA-LNPs into activated human primary T cells.

 

CD19 CAR_A
CD19 CAR_B
CD19 CAR_C
Dose-dependent CD19 CAR expression and cell viabilities in primary T cells. A) Percent CD19 CAR expression and B) Corresponding flow histograms as detected by flow cytometry at the indicated 0.05 – 4.8 µg RNA/million cell dose. C) Corresponding percent cell viability normalized to untreated controls.  
Multi-Step T Cell Engineering for Off-the-Shelf Cell Therapy

Achieve highly efficient genome editing knockouts in combination with high levels of CD19 CAR expression. This allows for the engineering of functional and viable “universal” CAR T cells that effectively kill CD19+ tumor cells.

 

Multi-Step T Cell Engineering A
Multi-Step T Cell Engineering B
Multi-Step T Cell Engineering C
Multi-Step T Cell Engineering D

 

Multi-step T cell engineering for off-the-shelf cell therapy. A) Schematic illustration of experiment. mRNA-LNPs containing sgRNA + Cas9 mRNA were added to primary T cells. Cells expanded prior to treatment with CD19 CAR mRNA-LNPs. At 24 hours post CAR mRNA-LNP treatment, CD19+ T cell killing assay was conducted for 16 hours. B) TCR knockout efficiency was assessed. Starting sample was TCR negative selected to further purify the TCR- population. C) Left: Percent CD19 CAR expression 24 hours after treatment with CAR mRNA-LNPs at 3.2 μg RNA/million cells, when population is TCR+, or TCR−. Right: Corresponding cell viabilities, normalized to the untreated population. D) Functional killing of CD19+ B cells (SUP-B15) by either UT, TCR+/CAR+, or gene-edited TCR−/CAR+ T cells at the indicated effector to target ratios (E:T). For all, a dose of 3.2 μg RNA/million cells was applied. Error bars represent standard deviation. Statistical significance was evaluated using t-tests or one-way ANOVA among the shown groups.
Seamlessly Scale from Discovery to Preclinical

The GenVoy-ILM T Cell Kit for mRNA is available on the NanoAssemblr Spark and Ignite instruments.

 

Discovery
Discovery 
Estimated RNA input: 0.01 mg
Estimated CAR T cells: 10 million
Preclinical
Preclinical 
Estimated RNA input: 2–4 mg
Estimated CAR T cells: 350–700 million
PD to GMP
PD to GMP
Instruments: NanoAssemblr Blaze™ and GMP 

 

Scale up from discovery to preclinical with a peace of mind. The NanoAssemblr microfluidic platform enables robust and equivalent performance of the GenVoy-ILM T Cell Kit for mRNA, Ignite to the GenVoy-ILM T Cell Kit for mRNA, Spark. These data demonstrate the seamless scalability from discovery to preclinical studies.

 

Scale Up_A
Scale Up_B
Scale Up_C
Scale Up_D
Scale Up_E

 

GenVoy-ILM T Cell Kit for mRNA scale up from NanoAssemblr Spark to Ignite. A) GFP and B) CD19 CAR transfection efficiency 24 hours post mRNA-LNP addition. C) Levels of single target (T cell receptor, TCR) knockout, and D) Double target (TCR and CD52) knockout through sgRNA and Cas9 mRNA delivery. E) Functional killing of CD19+ B cells (SUP-B15) in a 16 hour co-culture experiment. For all: a dose of 3.2 μg RNA/million cells was applied to human primary T cells. RNA-LNPs were prepared according to the GenVoy-ILM T Cell Kit for mRNA on Spark or Ignite User Guides. Average gene expression and gene knockout was detected by flow cytometry showing at minimum n=8 independent RNA-LNP preparations and n=2 donors. Functional killing performance was detected by flow cytometry showing n=2 independent RNA-LNP preparations and n=2 donors. Error bars represent standard deviation with statistical significance evaluated using t-tests among selected groups.
Easily Integrated into Standard T Cell Culture Protocols

Integrate into any standard T cell manufacturing workflow for both mRNA-based gene expression and CRISPR/Cas gene editing applications. See examples of the workflows as outlined below after preparing RNA-LNP on the NanoAssemblr Ignite instrument. 

 

Easily Integrated into Standard T Cell Culture Protocols Figure
Product Information

GenVoy-ILM T Cell Kit for mRNA, Ignite is a pre-blended lipid mix in ethanol and is available in two sizes.

 

T Cell Kit Ignite Box and Vials 3ml

 

GenVoy-ILM T Cell Kit for mRNA, Ignite, 3 mL (1001144)

 

Components: 

  • Lipid Mix, 3 mL 
  • Formulation Buffer (10X), 2 mL 
  • Dilution Buffer (10X), 40 mL 
  • Cryopreservation Buffer (2X), 3 mL 
  • Apolipoprotein-E3 (ApoE), 500 µg 

T Cell Kit Ignite Box and Vials 6ml

 

GenVoy-ILM T Cell Kit for mRNA, Ignite, 6 mL (1001161)

 

Components: 

  • Lipid Mix, 6 mL 
  • Formulation Buffer (10X), 4 mL 
  • Dilution Buffer (10X), 80 mL 
  • Cryopreservation Buffer (2X), 6 mL 
  • Apolipoprotein-E3 (ApoE), 500 µg x 2 

 

 

Contact a Specialist

Instruments, Cartridges and Accessories

The GenVoy-ILM T Cell Kit for mRNA, Ignite is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr Ignite instrument and cartridges.
Ignite is simple to use and can be operated with little to no training. Formulations can be completed in under a minute and made on demand to quickly optimize experimental parameters.
NanoAssemblr Ignite cartridges feature exclusive NxGen microfluidic technology that allows future scale up through a single mixer from mL/min to L/h. No priming or cleaning is required for an efficient workflow.
T Cell Kit Pipetting

Additional Resources

Application Note

March 15, 2022

Genome Editing of Human Primary T Cells with Lipid Nanoparticles

Read More 阅读更多 PDF

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Select...

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. F...

Read More 阅读更多

Publication - Abstract

May 08, 2020

Vaccines

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner a...

Read More 阅读更多

Publication - Abstract

May 31, 2019

Vaccine

mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerate...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith...

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid Nanoparticle-mediated siRNA Delivery for Safe Targeting of Human CML In Vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, M. Heuser et al.

Read More 阅读更多

Publication - Summary

May 17, 2019

Science Immunology

A Lipid-encapsulated mRNA Encoding a Potently Neutralizing Human Monoclonal Antibody Protects Against Chikungu...

N. Kose, J.M. Fox, G. Sapparapu, R. Bombardi, R.N. Tennekoon, A.D. de Silva, S.M. Elbashir...

Read More 阅读更多
Resource Center 资源中心